Conditions: Deleterious BARD1 Gene Mutation; Deleterious BRCA1 Gene Mutation; Deleterious BRCA2 Gene Mutation; Deleterious BRIP1 Gene Mutation; Deleterious EPCAM Gene Mutation; Deleterious MLH1 Gene Mutation; Deleterious MSH2 Gene Mutation; Deleterious MSH6 Gene Mutation; Deleterious PALB2 Gene Mutation; Deleterious PMS2 Gene Mutation; Deleterious RAD51C Gene Mutation; Deleterious RAD51D Gene Mutation; Hereditary Breast and Ovarian Cancer Syndrome; Premenopausal
Interventions: Other: Laboratory Biomarker Analysis; Procedure: Oophorectomy; Other: Quality-of-Life Assessment; Procedure: Salpingectomy; Procedure: Salpingo-Oophorectomy
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Active, not **RECRUITING NOW**
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
